Short answer
NeuroPace Inc (NPCE) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $23M (down 15.5% year over year) with net income of −$3M.
Q3 2026 key financials · XBRL
- Revenue
- $23M
- −15.5% YoY · +1.5% QoQ
- Net income
- −$3M
- +5.7% YoY · +46.8% QoQ
- Operating margin
- -9.0%
- Gross margin
- 84.3%
- EPS (diluted)
- −$0.10
- +9.1% YoY · +44.4% QoQ
Source: XBRL data from the NeuroPace Inc (NPCE) Q3 2026 10-Q on SEC EDGAR. USD.
NeuroPace Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $23.1M, down 1% YoY from $23.4M, driven by $0.6M lower service revenue
- Gross margin 84.3% vs 82.1% YoY, reflecting improved labor absorption and standard-cost benefits
- RNS System revenue up $0.3M, offsetting service-revenue decline; DIXI sales discontinued
- Cash, equivalents and short-term investments $49.2M, with $59.2M outstanding debt at September 30
- Operating cash flow use $12.6M vs $11.5M YoY; continued losses and negative cash flows expected near term
Risk Factors
- Newly added QMSR risk: QSR superseded on February 2, 2026, raising compliance requirements for the Mountain View manufacturing facility
- Most materially updated regulatory risk: FDA staffing cuts and leadership changes could delay expanded-label reviews for IGE and ages 12 to 17
- Healthcare reform risk: OBBBA expected to reduce Medicaid spending and enrollment, potentially shrinking coverage for RNS procedures
- Operational risk: single-source suppliers include Micro Systems Technologies and Integer for printed circuit assemblies and batteries
- Margin risk: changing tariff framework could weaken RNS gross margins and revenue projections despite limited non-U.S. supply-chain activity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NeuroPace Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.